By Katherine Eban
FORTUNE -- Indian generic drug-maker Ranbaxy Laboratories pleaded guilty Monday to seven federal criminal counts of selling adulterated drugs with intent to defraud, failing to report that its drugs didn't meet specifications, and making intentionally false statements to the government.
As part of the proceedings in Baltimore federal court Monday morning, a whistleblower lawsuit against Ranbaxy was also unsealed. The company will pay a total of $500 million in criminal and civil penalties to resolve the criminal case and the whistleblower suit.
Ranbaxy has been grappling with quality issues for years. In 2008, the Food & Drug Administration took a highly unusual step, barring the importation of 30 drugs from two of Ranbaxy's plants in India. The FDA slapped the company with what's called an "Application Integrity Policy," halting the review of new drug applications from one of the company's Indian facilities until Ranbaxy proved its truthfulness.
The U.S. Department of Justice added more restrictions in January 2012, when it placed Ranbaxy under a sweeping consent decree. This time Ranbaxy was barred from selling drugs in the U.S.that were made at several of its Indian plants until the quality could be verified. The Justice Department also required the company to undergo independent auditing.
Despite the ongoing regulatory and legal travails, in November 2011, the FDA allowed Ranbaxy to proceed with exclusive first rights to sell a generic version of the anti-cholesterol medication Lipitor. One year later, Ranbaxy recalled 41 lots of generic Lipitor after glass particles were found inside them. In March of this year, the FDA permitted Ranbaxy to resume sales of the drug, and Fortune has learned that the U.S. Dept. of Veterans Affairs recently signed a large contract to buy the Ranbaxy drug, according to a company insider.
In several days, Fortune will publish a lengthy investigation examining the fraud at Ranbaxy.
The generic pharmaceutical company made its debut on the Fortune 500 this year at No. 432.
By Brian O'Keefe, assistant managing editor
This is the first in a regular series of stories that will be focused on people, companies, and trends in the Fortune 500.
Fortune -- How do things change for a company on the day when it officially joins the Fortune 500? Is the status upgrade a transformative event? Does MOREMay 10, 2013 11:21 AM ET
China will spend billions on biotech, even as the industry struggles in the U.S. to turn research into gold. Will U.S. biotech become the next Detroit?
By David Ewing Duncan, contributor
FORTUNE -- Now it's China's turn to fling lots of cash at trying to come up with cures.
For more than a decade, the U.S. has lavished funding on efforts to transform a wealth of biological breakthroughs in the lab into actual MOREAug 15, 2011 12:20 PM ET
|Fast food worker: Protest didn't cost me pay|
|2 million Facebook, Gmail and Twitter passwords stolen in massive hack|
|Job growth drives mortgage rate jump|
|GM to discontinue Chevrolet brand in Europe|
|Ron Paul: Bitcoin could 'destroy the dollar'|